Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is approximately 9.11 % above the present share price of $76.07.
Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the earliest quarter of 2021.
The analysts price targets range from a high of $101 to a low of $61.
From the latest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is $99.57 billion.
Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It works through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management strategies. The Long or retail Term Care segment has offering of prescription drugs as well as assortment of general merchandise.
The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products as well as associated services, which includes medical, pharmacy, dental, behavioural health, medical relief abilities. The Corporate segment involves in offering administrative services and management. The company was founded by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.